An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Down syndrome (DS) is one of the most common causes of intellectual disability, due to trisomy of all or part of chromosome 21. DS is also associated with the development of Alzheimer disease (AD) neuropathology after the age of 40 years. To better clarify the cellular and metabolic pathways that could contribute to the differences in DS brain, in particular those involved in the onset of neurodegeneration, we analyzed the frontal cortex of DS subjects with or without significant AD pathology in comparison with age-matched controls, using a proteomics approach. Proteomics represents an advantageous tool to investigate the molecular mechanisms underlying the disease. From these analyses, we investigated the effects that age, DS, and AD neuropathology could have on protein expression levels. Our results show overlapping and independent molecular pathways (including energy metabolism, oxidative damage, protein synthesis and autophagy) contributing to DS, to aging and to the presence of AD pathology in DS. Investigation of pathomechanisms involved in DS with AD, may provide putative targets for therapeutic approaches to slow the development of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β-peptide
Butterfield, D. A., Drake, J., Pocernich, C., & Castegna, A. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02173-6 · Cited by 1,114
Self-citationMitochondrial abnormalities in Alzheimer brain: Mechanistic implications
Bubber, P., Haroutunian, V., Fisch, G., Blass, J. P., & Gibson, G. E. (2005) · Annals of Neurology · doi:10.1002/ana.20474 · Cited by 622
Lemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., & Selkoe, D. J. (1996) · Neurobiology of Disease · doi:10.1006/nbdi.1996.0003 · Cited by 584 · cited 2×
“Aβ deposition in DS brains begins in the early years of life, as young as 8 years, and increases progressively with increasing age [13,14].”
BackgroundA Prospective Study of Alzheimer Disease in Down Syndrome
Lai, F., & Williams, R. S. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520440031017 · Cited by 561 · cited 1×
“In addition to intellectual disability, virtually all DS brains over 40 years of age show Alzheimer disease (AD) neuropathology [3], including the presence of senile plaque (SP) and neurofibrillary tangles [3–5], and clinical signs of dementia become more frequent after 50 years of age [6,7].”
BackgroundValosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease
Ju, J.-S., Fuentealba, R. A., Miller, S. E., Jackson, E., Piwnica-Worms, D., Baloh, R. H., & Weihl, C. C. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200908115 · Cited by 494 · cited 1×
“In addition to the above, an intriguing result of our study is suggested by the protein TER ATPase, also called valosincontaining protein (VCP), essential for autophagic processes [58].”
BackgroundMann, D. M. A., & Esiri, M. M. (1989) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(89)90019-1 · Cited by 471 · cited 1×
“In addition to intellectual disability, virtually all DS brains over 40 years of age show Alzheimer disease (AD) neuropathology [3], including the presence of senile plaque (SP) and neurofibrillary tangles [3–5], and clinical signs of dementia become more frequent after 50 years of age [6,7].”
BackgroundButterfield, D. A., Poon, H. F., St. Clair, D., Keller, J. N., Pierce, W. M., Klein, J. B., & Markesbery, W. R. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.11.002 · Cited by 377 · cited 4×
“Furthermore, in an early stage of AD, mild cognitive impairment (MCI), EF-Tu was found excessively bound to the lipid peroxidation product 4-hydroxy-2-nonenal (HNE) compared to control, leading to protein dysfunction and neuronal death [32].”
BackgroundSelf-citationReed, T., Perluigi, M., Sultana, R., Pierce, W. M., Klein, J. B., Turner, D. M., Coccia, R., Markesbery, W. R., & Butterfield, D. A. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.12.007 · Cited by 257 · cited 1×
“Furthermore, in an early stage of AD, mild cognitive impairment (MCI), EF-Tu was found excessively bound to the lipid peroxidation product 4-hydroxy-2-nonenal (HNE) compared to control, leading to protein dysfunction and neuronal death [32].”
BackgroundSelf-citationReed, T. T., Pierce, W. M., Markesbery, W. R., & Butterfield, D. A. (2009) · Brain Research · doi:10.1016/j.brainres.2009.04.009 · Cited by 190 · cited 1×
“Further, MDH was also covalently bound by HNE in early AD in the inferior parietal lobule compared to similarly aged control brain [49].”
BackgroundGenetic and host factors for dementia in Down's syndrome
Schupf, N. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.5.405 · Cited by 188 · cited 2×
“This abnormal chromosomal condition leads to a wide heterogeneity in DS phenotypes [28], among which age-associated neuropathology is a consistent feature [20].”
Background
Cited by
Butterfield, D. A., & Boyd-Kimball, D. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170543 · Cited by 403
Self-citationTramutola, A., Triplett, J. C., Di Domenico, F., Niedowicz, D. M., Murphy, M. P., Coccia, R., Perluigi, M., & Butterfield, D. A. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13037 · Cited by 347
Self-citationA review of the mechanisms underlying selected comorbidities in Alzheimer’s disease
Maciejewska, K., Czarnecka, K., & Szymański, P. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00293-5 · Cited by 64
Protto, V., Tramutola, A., Fabiani, M., Marcocci, M. E., Napoletani, G., Iavarone, F., Vincenzoni, F., Castagnola, M., Perluigi, M., Di Domenico, F., et al. (2020) · Microorganisms · doi:10.3390/microorganisms8070972 · Cited by 36
Metadata
- Authors
- Cenini, G., Fiorini, A., Sultana, R., Perluigi, M., Cai, J., Klein, J. B., Head, E., & Butterfield, D. A.
- Venue
- Free Radical Biology and Medicine
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 76
- Pages
- 89-95
- ISSN
- 0891-5849 (ISSN-L)
- OpenAlex
- W1980655462
- Cited by
- 26
- References
- 11
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach. https://app.cochat.ai/papers/10.1016/j.freeradbiomed.2014.08.006
- The paper
- Cenini, G., Fiorini, A., Sultana, R., Perluigi, M., Cai, J., Klein, J. B., Head, E., & Butterfield, D. A. (2014). An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach. Free Radical Biology and Medicine. https://doi.org/10.1016/j.freeradbiomed.2014.08.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.